Uncategorized
Encore Vision begins enrollment for phase 1/2 study of presbyopia drug
The first patient has been enrolled in Encore Vision’s phase 1/2 trial of EV06, an investigational topical treatment for presbyopia, according to a company press release. EV06 (lipoic acid choline ester) is a compound being developed to reverse age-related changes in the crystalline lens that result in diminished lens elasticity.